Pertuzumab for Breast Cancer: 42 Real Stories

42 stories match breast cancer and pertuzumab. 31 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage II Breast Squamous Cell CarcinomaBreast Cancer

HER2-positive squamous cell breast cancer in complete remission

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: HER2-positive squamous cell breast cancer, ER/PR negative, PD-L1 negative

Clinical complete remission and survival beyond 4 years after mastectomy, AC-TH chemotherapy, and HER2-directed maintenance therapy for Stage IIA HER2-positive primary squamous cell breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-Positive Breast Cancer That Spread to the Cervix

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive; ER and PR less than 1% in the left breast tumor

Metastatic Site: cervix, esophagus, mediastinal lymph nodes

Cervical metastasis showed a local complete response after brachytherapy, but systemic disease later progressed to the esophagus. She died after 4 months of nutritional support and palliative treatment.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 invasive ductal carcinoma: metastatic disease with bone involvement managed successfully

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER <1%; PR 0%; HER2 score 3+; Ki-67 60%

Metastatic Site: bone (12th thoracic vertebra/T12)

Stage IV HER2-positive breast cancer had improved T12 bone metastasis, major breast-tumor regression on trastuzumab deruxtecan, and pathologic complete response in the breast after mastectomy; durable systemic disease status was not reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Triple-positive breast cancer: complete response to targeted therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer; SBDS variants present; no detected TP53 variant on MyeloSeq.

Metastatic Site: liver

Stage IV triple-positive breast cancer with liver metastasis achieved complete response after paclitaxel, trastuzumab, pertuzumab, and G-CSF support; complete response was maintained for 18 months after treatment initiation while on maintenance HER2-directed and endocrine therapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV triple-negative breast cancer in remission: CBD and exercise for neuropathy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative breast cancer. Blood and immune inflammation measures were tracked during neuropathy care.

Metastatic Site: liver

She was in remission for more than 5 years after Stage IV breast cancer with a solitary liver metastasis, while later managing chemotherapy-induced peripheral neuropathy with CBD and an exercise program that improved symptoms and function.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic HER2-Positive Breast Cancer With Treatment-Related Telangiectasias

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive; initially ER-negative and PR-negative; metastatic disease weakly ER-positive and PR-negative; germline testing negative

Metastatic Site: left supraclavicular, mediastinal, axillary and…

Living with HER2-positive breast cancer for 9+ years since her 2014 diagnosis, including metastatic disease since 2017. She remained on reduced-dose tucatinib in 2023 while treatment-related telangiectasias improved after dose reduction and electrocautery.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic breast cancer: three years in remission with T-DM1 (Kadcyla) treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; hormone receptor-positive

Metastatic Site: liver; spine / bone

T-DM1 produced a complete clinical and radiological response after 7 cycles, sustained for 41 months and 60 cycles while treatment continued.

PubMed Central
OutcomeComplete Response
Olivia, who was diagnosed with Stage IV Inflammatory Breast CancerBreast Cancer

Stage IV HER2-Positive Inflammatory Breast Cancer: Olivia's Survivor Story

Patient Info: Olivia Franz, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Bones; distant lymph nodes

As of October 2023, Olivia continued to show no evidence of disease on scans while receiving maintenance trastuzumab and pertuzumab every 3 weeks and zoledronic acid every 3 months for bone health.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Breast Cancer Treatment Caused Severe Circulation Problems in Her Fingers and Toes

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; ER-negative; PR-negative

The digital ischaemia improved after gemcitabine was stopped, without revascularisation, debridement or amputation, although a small necrotic fingertip area persisted at 3 months. Metastatic breast cancer treatment continued with further systemic lines after progression.

PubMed Central
OutcomeLiving With Cancer / Ongoing Treatment
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer diagnosed during pregnancy and later spread to bone and brain

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Initial tumour: ER 0%, PR <1%, HER2 3+

Metastatic Site: bone (L3)|brain

After treatment and surveillance without new lesions, she developed a large symptomatic occipital brain metastasis 14 months after completing paclitaxel and radiation and died after rapid neurological deterioration.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

HER2-Positive Breast Cancer Linked to a Rare Immune-Related Neurological Syndrome

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive in both foci; one focus ER-negative/PR-positive with Ki-67 45%; second focus ER-negative/PR-negative with Ki-67 35%; anti-Yo antibodies positive in serum and CSF; tumour-susceptibility gene panel negative

At 1 year, she had completed trastuzumab, continued tamoxifen, and had no evidence of recurrent breast cancer; intensive rehabilitation improved her mobility, although balance and right-sided neurological deficits persisted.

PubMed Central
OutcomeCancer-Free / NED
Christine, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine Hodgdon, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Christine had no evidence of disease after 1 year and continued HER2-targeted treatment with regular surveillance scans.

AACR
OutcomeCancer-Free / NED
Kate, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Kate's Survivor Story

Patient Info: Kate Watson, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Chest lymph nodes; spine; pelvis; femur

As of October 2019, Kate had been in remission for about 3 years with regular PET scans showing no evidence of active disease, while continuing monthly HER2-targeted maintenance treatment.

Cleveland Clinic
OutcomeCancer-Free / NED